Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Matinas BioPharma Holdings, Inc.
Report date June 29, 2017 · Filed July 03, 2017
Jointly reported with Lorenzo Jennifer, GJG Life Sciences, LLC
Section 16 reporting ended · disclosed 2017-07-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy GJG Life Sciences, LLC | 0 |
Reported balance
After 2017-06-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-06-28 · Other · Disposed 10,496,760 · Balance 0 F1: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. |
| Common StockSEC Table I · non-derivative | Direct | 2,086,576 |
Reported balance
After 2017-06-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-06-28 · Other · Acquired 1,565,333 · Balance 2,086,576 F1: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. |
| Class A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 | IndirectBy GJG Life Sciences, LLC | 3,950,000 |
Reported balance
Holding disclosure · report date 2017-06-29 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,950,000 F2: GJG Life Sciences, LLC is the direct owner of Class A Convertible Preferred Stock of Matinas (the "Class A Preferred"). The Class A Preferred will convert automatically into Matinas common stock upon the earlier of (i) notice by Matinas to the holders that Matinas elected to convert all outstanding shares of Class A Preferred, (ii) three years from July 29, 2016, (iii) the approval of Matinas' MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of Matinas' MAT2501 product candidate. The reporting person is the Managing Member of GJG Capital, LLC and, as a result, the reporting person and GJG Capital, LLC may be deemed to be indirect beneficial owners of the reported securities. Jennifer Lorenzo and GJG Capital, LLC disclaim beneficial ownership of the Class A Preferred Stock except to the extent of their respective pecuniary interest. F1: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. |
| Class A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 | IndirectBy GJG Life Sciences, LLC | 950,000 |
Reported balance
Holding disclosure · report date 2017-06-29 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 950,000 F2: GJG Life Sciences, LLC is the direct owner of Class A Convertible Preferred Stock of Matinas (the "Class A Preferred"). The Class A Preferred will convert automatically into Matinas common stock upon the earlier of (i) notice by Matinas to the holders that Matinas elected to convert all outstanding shares of Class A Preferred, (ii) three years from July 29, 2016, (iii) the approval of Matinas' MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of Matinas' MAT2501 product candidate. The reporting person is the Managing Member of GJG Capital, LLC and, as a result, the reporting person and GJG Capital, LLC may be deemed to be indirect beneficial owners of the reported securities. Jennifer Lorenzo and GJG Capital, LLC disclaim beneficial ownership of the Class A Preferred Stock except to the extent of their respective pecuniary interest. F1: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC.
F2: GJG Life Sciences, LLC is the direct owner of Class A Convertible Preferred Stock of Matinas (the "Class A Preferred"). The Class A Preferred will convert automatically into Matinas common stock upon the earlier of (i) notice by Matinas to the holders that Matinas elected to convert all outstanding shares of Class A Preferred, (ii) three years from July 29, 2016, (iii) the approval of Matinas' MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of Matinas' MAT2501 product candidate. The reporting person is the Managing Member of GJG Capital, LLC and, as a result, the reporting person and GJG Capital, LLC may be deemed to be indirect beneficial owners of the reported securities. Jennifer Lorenzo and GJG Capital, LLC disclaim beneficial ownership of the Class A Preferred Stock except to the extent of their respective pecuniary interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2017 Filed Jul 3, 2017 14:02 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock | 1,565,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000603 · lorenzo_4.xml · nonDerivative · entry 2 Lorenzo Jennifer · CIK 0001697285 · Shareholder GJG Life Sciences, LLC · CIK 0001582638 · Shareholder GJG Capital, LLC · CIK 0001698996 · Shareholder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086,576 F1 · kind: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. F1 · price: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. F1 · balance_after: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. F1 · ownership.direct: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. Read SEC document |
| June 28, 2017 Filed Jul 3, 2017 14:02 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock | 10,496,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000603 · lorenzo_4.xml · nonDerivative · entry 1 Lorenzo Jennifer · CIK 0001697285 · Shareholder GJG Life Sciences, LLC · CIK 0001582638 · Shareholder GJG Capital, LLC · CIK 0001698996 · Shareholder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GJG Life Sciences, LLC Disclosed balance after: 0 F1 · kind: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. F1 · price: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. F1 · balance_after: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. F1 · ownership.direct: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. F1 · ownership.nature: On June 29, 2017, GJG Life Sciences, LLC distributed to its Members, pro-rata without consideration, 10,496,760 shares of Matinas common stock. Of such shares, 8,931,427 shares were distributed to the Class A Members and the remaining 1,565,333 shares were distributed to the reporting person, the Managing Member of the Class B Member, GJG Capital, LLC. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 10:29 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherWarrant (right to buy) · Derivative | 1,369,169 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001019056-17-000294 · lorenzo_4.xml · derivative · entry 3 Lorenzo Jennifer · CIK 0001697285 · 10% owner GJG Life Sciences, LLC · CIK 0001582638 · 10% owner GJG Capital, LLC · CIK 0001698996 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GJG Life Sciences, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,369,169 shares Expires 2020-03-30 F1 · ownership.direct: On March 15, 2017 GJG Life Sciences, LLC exercised a warrant to purchase 1,369,169 shares of Matinas common stock at an exercise price of $0.75 a share. The warrant was owned directly by GJG Life Sciences, LLC, a limited liability company of which GJG Capital, LLC is the Managing Member. The reporting person is the Managing Member of GJG Capital, LLC and, as a result, the reporting person and GJG Capital, LLC may be deemed to be indirect beneficial owners of the reported securities. Jennifer Lorenzo and GJG Capital, LLC disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest. The reporting person is the direct owner of 521,243 shares of Matinas common stock. F1 · ownership.nature: On March 15, 2017 GJG Life Sciences, LLC exercised a warrant to purchase 1,369,169 shares of Matinas common stock at an exercise price of $0.75 a share. The warrant was owned directly by GJG Life Sciences, LLC, a limited liability company of which GJG Capital, LLC is the Managing Member. The reporting person is the Managing Member of GJG Capital, LLC and, as a result, the reporting person and GJG Capital, LLC may be deemed to be indirect beneficial owners of the reported securities. Jennifer Lorenzo and GJG Capital, LLC disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest. The reporting person is the direct owner of 521,243 shares of Matinas common stock. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 10:29 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock | 1,369,169 | $0.75 | $1,026,876.75 |
DisclosureSEC source: 0001019056-17-000294 · lorenzo_4.xml · nonDerivative · entry 1 Lorenzo Jennifer · CIK 0001697285 · 10% owner GJG Life Sciences, LLC · CIK 0001582638 · 10% owner GJG Capital, LLC · CIK 0001698996 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GJG Life Sciences, LLC Disclosed balance after: 10,496,760 F1 · balance_after: On March 15, 2017 GJG Life Sciences, LLC exercised a warrant to purchase 1,369,169 shares of Matinas common stock at an exercise price of $0.75 a share. The warrant was owned directly by GJG Life Sciences, LLC, a limited liability company of which GJG Capital, LLC is the Managing Member. The reporting person is the Managing Member of GJG Capital, LLC and, as a result, the reporting person and GJG Capital, LLC may be deemed to be indirect beneficial owners of the reported securities. Jennifer Lorenzo and GJG Capital, LLC disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest. The reporting person is the direct owner of 521,243 shares of Matinas common stock. F1 · ownership.direct: On March 15, 2017 GJG Life Sciences, LLC exercised a warrant to purchase 1,369,169 shares of Matinas common stock at an exercise price of $0.75 a share. The warrant was owned directly by GJG Life Sciences, LLC, a limited liability company of which GJG Capital, LLC is the Managing Member. The reporting person is the Managing Member of GJG Capital, LLC and, as a result, the reporting person and GJG Capital, LLC may be deemed to be indirect beneficial owners of the reported securities. Jennifer Lorenzo and GJG Capital, LLC disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest. The reporting person is the direct owner of 521,243 shares of Matinas common stock. F1 · ownership.nature: On March 15, 2017 GJG Life Sciences, LLC exercised a warrant to purchase 1,369,169 shares of Matinas common stock at an exercise price of $0.75 a share. The warrant was owned directly by GJG Life Sciences, LLC, a limited liability company of which GJG Capital, LLC is the Managing Member. The reporting person is the Managing Member of GJG Capital, LLC and, as a result, the reporting person and GJG Capital, LLC may be deemed to be indirect beneficial owners of the reported securities. Jennifer Lorenzo and GJG Capital, LLC disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest. The reporting person is the direct owner of 521,243 shares of Matinas common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.